Pfizer ($PFE) may finally be turning the corner on its post-pandemic revenue challenges. The company recently reported ...

The rising bladder cancer star that is the combination of Pfizer and Astellas’ Padcev and Merck’s Keytruda is looking to set ...

Padcev, an antibody-drug conjugate which Pfizer acquired via its $43 billion Seagen deal, could help people who don’t qualify ...

Pfizer PFE is one of the largest and most successful drugmakers in oncology. It boasts a strong portfolio of approved cancer ...

Pfizer Inc. and Astellas Pharma Inc. have announced positive topline results from the Phase 3 EV-303 clinical trial (also ...

In the EV-303/KEYNOTE-905 study, the combination of nectin-4-directed antibody-drug conjugate (ADC) Padcev (enfortumab ...

Pfizer said its antibody-drug conjugate Padcev extended survival when combined with the immunotherapy Keytruda in some ...

Roche has found redemption in a precision medicine approach following an earlier Tecentriq trial flop in a broader bladder ...

Merck's Phase 3 trial shows Keytruda plus Padcev improves survival in muscle-invasive bladder cancer patients ineligible for ...

Pfizer beats Q2 estimates with rising oncology sales, new drug launches, and strong Seagen-driven portfolio growth.

Pfizer & Astellas announce Padcev plus Keytruda significantly improves survival for certain patients with bladder cancer when given before and after surgery: New York Wednesday, A ...

“These results from EV-303 represent a breakthrough for cisplatin-ineligible patients with muscle-invasive bladder cancer, demonstrating the potential of PADCEV in combination with KEYTRUDA when used ...